Jun 10, 2026 | Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3

Jun 23, 2026 | Pfizer Seagen ADC Fails in Lung Cancer Phase 3; CMS Settles Opzelura Classification

Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vaccine wins unanimous FDA panel support. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Seagen, sigvotatug vedotin, ADC, antibody-drug conjugate, non-small cell lung cancer, NSCLC, Incyte, Opzelura, Jakafi, ruxolitinib, CMS, Medicare Part D, Sangamo Therapeutics, zinc-finger nuclease, gene editing, Eli Lilly, Astellas, Moderna, mFlusiva, flu vaccine, Regenxbio, UniQure, gene therapy, Makary, Genentech, Novartis, Xolair, Braftovi, encorafenib, 340B, Sanofi, Houman Ashrafian, Bionyra, Osanni Bio, Lilly, AstraZeneca, Merck

Jun 22, 2026 | AbbVie's $10.9B Apogee Buy Targets Dupixent; 1st Solid Tumor CAR-T Approved in China

AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase 3 win, and HHS clinical trial reforms target China.   Visit www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, AbbVie, Apogee Therapeutics, zumilokibart, Dupixent, Regeneron, Sanofi, CARsgen, CAR-T, Claudin 18.2, solid tumor, gastric cancer, Merck, Prometheus Biosciences, IBD, Keytruda, HHS, RFK Jr, clinical trial reform, Moderna, mFlusiva, Alnylam, Pfizer, Kardigan, MacroGenics, TZIELD, Bionyra, cAMPfield, WuXi Biologics, Novartis, pelacarsen, UniQure, AMT-130, Novo Nordisk, ransomware, BMS

Jun 19, 2026 | US Probes Germany Drug Pricing; Moderna Flu Vaccine Wins Unanimous FDA Panel

US government opens formal probe into Germany's drug pricing reforms, escalating transatlantic pharma trade tensions. Kardigan IPO raises $400M and pops 31%. Moderna flu vaccine gets unanimous FDA advisory panel support ahead of Aug 5 PDUFA. Jazz and AbCellera strike $4.1B T cell engager collaboration. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Germany drug pricing, US trade probe, Moderna flu vaccine, mFlusiva, Kardigan IPO, Jazz Pharmaceuticals, AbCellera, T cell engagers, Pfizer CFO Dave Denton, Eli Lilly, 4E Therapeutics, Edgewise Biosciences, HCM, Biogen, RayThera, Traws Pharma, tivoxavir marboxil, Merck Capvaxive, Treasury China biotech, cAMPfield, Vedana Therapeutics, Spot Bio, Innoviva, Lyndra, Sanofi, Aurobindo, Lannett, Pfizer, Lilly, Merck, Moderna

Jun 18, 2026 | Moderna mFlusiva Wins Unanimous VRBPAC Vote; NovoCure TRIDENT Fails in GBM

Moderna's mRNA flu vaccine gets unanimous FDA panel backing — PDUFA August 5. NovoCure's TRIDENT trial misses overall survival in glioblastoma; stock drops ~18%. Biogen acquires immunology startup RayThera for up to $1B; Kardigan IPO raises $400M. Visit us at www.thepharmacloseput.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Moderna, mFlusiva, MRNA, VRBPAC, mRNA flu vaccine, NovoCure, NVCR, TRIDENT, glioblastoma, TTFields, Biogen, BIIB, RayThera, immunology, Pfizer, PFE, CFO, Kardigan, IPO, cAMPfield, Legend Biotech, LEGN, Carvykti, Eli Lilly, 4E Therapeutics, Merck, Capvaxive, pneumococcal vaccine, Innoviva, Lyndra, Aurobindo, Lannett, FTC, Treasury, China biotech, Lilly, GSK, Sanofi

Jun 17, 2026 | UniQure AMT-130 Surges 70% on FDA Reversal; Jazz-AbCellera $4.1B TCE Deal

UniQure surges 70% as FDA reverses course on Huntington's gene therapy AMT-130 filing path. Jazz and AbCellera strike $4.1B T cell engager deal for GI cancers. Novo Nordisk faces $25M ransom demand after hackers claim drug formulations and AI models.   Visit www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, UniQure, QURE, AMT-130, Huntington's disease, gene therapy, FDA accelerated approval, Jazz Pharmaceuticals, AbCellera, T cell engagers, Novo Nordisk, cyberattack, data breach, Biogen, RayThera, immunology, Moderna, mFlusiva, VRBPAC, mRNA flu vaccine, GSK, Spero Therapeutics, complicated UTI, compounded GLP-1, Vedana Biosciences, Spot Bio, Triveni Bio, Colorado drug importation